Judge dismisses most of Wang’s claims against Pitt and UPMC

On Dec. 21, U.S. District Judge Marylyn J. Horan for the Western District of Pennsylvania, dismissed most of the claims from a lawsuit from Norman Wang, an embattled School of Medicine professor who penned a controversial white paper that criticized the effectiveness of affirmative action efforts in the medical field.

The article was published in the Journal of the American Heart Association in March 2020. The paper resurfaced in August 2020 to heavy criticism from cardiologists, and the JAHA retracted the paper that month saying that it did not represent the organization's values. In response to the backlash against the paper, UPMC removed Wang from his position as program director of the UPMC Electrophysiology Fellowship in August. 

Wang, who filed the lawsuit in December 2020, claimed Pitt, UPMC, the American Heart Association, the University of Pittsburgh Physicians group (UPP), which is owned by UPMC, and three doctors who work for UPMC and teach at Pitt violated his First Amendment rights, and also claimed defamation for statements allegedly claiming Wang misused academic sources. He also sued the American Heart Association and Wiley Publications, which publishes JAHA online.

In dismissing the allegations against Pitt, the court’s opinion said several times that the actions taken by UPP and the doctors were taken under their role as UPMC physicians, not as faculty in the School of Medicine.

Pitt has repeatedly said that the actions taken against Wang were done by UPMC, which has been a separate legal entity from the University of Pittsburgh since 1998. 

The judge’s opinion did allow Wang to file a second amended complaint on some charges, which he did in January, alleging violations of his First Amendment rights by Pitt, UPMC, UPP and the three doctors.

Wang and University representatives did not respond to requests for comment.

— Susan Jones


Have a story idea or news to share? Share it with the University Times.

Follow the University Times on Twitter and Facebook.